Will lanreotide (Somatostatin analogue) cause diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the FDA Drug Label

Lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Hence, patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia. Blood glucose levels should be monitored when lanreotide treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly [see Adverse Reactions (6.1)].

7.1 Insulin and Oral Hypoglycemic Drugs Lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Therefore, blood glucose levels should be monitored when SOMATULINE DEPOT treatment is initiated or when the dose is altered, and antidiabetic treatment should be adjusted accordingly [see Warnings and Precautions (5.2)].

Lanreotide may cause hyperglycemia due to its inhibition of insulin secretion. However, it will not directly make you diabetic.

  • Hyperglycemia is a possible side effect of lanreotide treatment.
  • Monitoring of blood glucose levels is recommended when initiating or altering lanreotide treatment.
  • Adjustments to antidiabetic treatment may be necessary 1, 1, 1.

From the Research

Lanreotide does not necessarily make you diabetic, but it can affect your blood sugar levels, with about 5-10% of patients developing high blood sugar or diabetes, as reported in various studies 2, 3, 4. This medication, which is used to treat conditions like acromegaly and neuroendocrine tumors, works by mimicking the hormone somatostatin, which can inhibit insulin release from the pancreas. The risk of developing high blood sugar or diabetes is higher if you already have pre-diabetes, take high doses, or have other risk factors for diabetes. During treatment, your doctor will monitor your blood sugar levels regularly, especially in the first few months. If you notice symptoms like increased thirst, frequent urination, or unexplained fatigue, contact your healthcare provider promptly. For most patients, any blood sugar changes can be managed with diet, exercise, or diabetes medications if needed. The benefits of lanreotide for your primary condition often outweigh this potential side effect, but discussing your specific risk factors with your doctor is important, as noted in a recent study 4. It's also worth noting that other medications, such as metformin and linagliptin, can be used to manage blood sugar levels, as shown in a study comparing high-dose metformin monotherapy with low-dose metformin/linagliptin combination therapy 5. However, the most recent and highest quality study on lanreotide, published in 2022, found that it is a well-tolerated treatment for patients with congenital hyperinsulinism, with a low risk of adverse effects on blood sugar levels 2. Therefore, lanreotide is a safe and effective treatment option for patients with certain medical conditions, and its potential impact on blood sugar levels can be managed with proper monitoring and care.

Related Questions

A 47-year-old obese patient with type 2 diabetes mellitus, baseline weight 120 kg, started on tirzepatide (Mounjaro) 2.5 mg then increased to 5 mg and maintained for 6–7 weeks, also taking dapagliflozin and metformin. At week 6 his weight was 113 kg, but over the past two weeks he reports paradoxical increased hunger, lethargy, and a weight plateau while still on 5 mg tirzepatide. What steps should be taken?
For a 70-year-old male weighing 128 kg with type 2 diabetes who is stopping tirzepatide (Mounjaro) 15 mg weekly, empagliflozin (Jardiance) 25 mg daily, and metformin 2000 mg daily while hospitalized, what should his initial insulin glargine (Lantus) dose, carbohydrate‑to‑insulin ratio, and correction factor be?
What’s the next step for a type 2 diabetic with high hemoglobin A1c and high random plasma glucose who is on Janumet (metformin + sitagliptin) and tirzepatide (Mounjaro) 10 mg weekly?
In a patient with an A1c of 7.9% (up from 7.7%) who is taking tirzepatide (Mounjaro) 5 mg weekly and metformin 500 mg daily, which medication should be added?
What treatment recommendations are appropriate for a 42‑year‑old woman taking escitalopram (Lexapro) 10 mg daily, tirzepatide (Zepbound) 12.5 mg weekly, metformin 1000 mg daily, and spironolactone 100 mg daily who has chronic fatigue, intermittent heat intolerance, brain fog, and irritability?
What are the key differentiating features of cholelithiasis (gallstones) versus cholecystitis (inflammation of the gallbladder) versus choledocholithiasis (common bile duct stones) versus cholangitis (inflammation of the bile ducts)?
What is the recommended treatment approach for patients with suspected asthma prior to fractional exhaled nitric oxide (FeNO) testing?
What is the treatment for a patient presenting with pyuria (21-50 white blood cells (WBC) per high power field), hematuria (greater than 30 red blood cells (RBC) per high power field), bacteriuria (many bacteria), significant hemoglobinuria (large amount of blood in urine), proteinuria (100 mg/dl of protein in urine), positive nitrate test, and small amount of leukocyte esterase?
What is the relationship between elevated granulocytes (white blood cells) and bacterial infection?
What are the UK guidelines for managing acne in an 11-year-old?
What is the relationship between abdominal pain and Graves' disease (Hyperthyroidism)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.